NVCR News and Press, NovoCure Limited From 03/27/24

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT No...

2024-03-25 11:19:34 ET Oppenheimer argued on Monday that the S&P 500 ( SP500 ) is poised for a move higher when looking back at macro similarities from 1987 to 1990. The key takeaway from the '87-'90 road map was that the Fed’s first rate cut proceeded the top in market bread...

2024-03-24 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ...

2024-02-22 12:15:13 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2023 Earnings Call Feb 22, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2023 Earnings Call Transcript

2024-02-21 11:34:50 ET More on NovoCure NovoCure: Stay Cautious Amid Positive Signs NovoCure Tumor Treating Fields accepted for FDA review Novocure reports better-than-expected preliminary Q4, FY revenue Seeking Alpha’s Quant Rating on NovoCure ...

2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...

2024-01-19 17:47:40 ET Summary NovoCure's FDA application for TTF in NSCLC accepted; approval expected in H2 2024. Preliminary Q4 results show $509M annual revenue. This is a slight increase from estimates but a 5% year-on-year decline. NovoCure's valuation struggles with tepi...

2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...

NovoCure Limited (NASDAQ: NVCR) is one of today's top gainers. The company's shares have moved 3.24% on the day to $13.05. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company...